Mucorales – Page 2

Comparison of the Filamentous Fungi Library v4.0 MALDI Biotyper Platform vs MSI-2 performance for identifying filamentous fungi from liquid cultures

mycolabadmin

This study compared two advanced technologies for identifying dangerous fungi in clinical samples. The MALDI Biotyper FFLv4.0 system identified about 96% of fungi correctly when using liquid culture samples, outperforming the MSI-2 database which identified about 78.5%. Both systems had difficulty with certain difficult-to-distinguish species, especially within Aspergillus and Fusarium groups, but performed well with Mucorales fungi. The findings suggest that continuous updating of these fungal identification libraries is essential for improving patient care.

Prevalence of fungi and their antifungal and disinfectant resistance in hospital environments: insights into combating nosocomial mycoses

mycolabadmin

This study examined how fungal infections spread in hospital settings by testing air and surfaces in Iranian hospital intensive care units. Researchers found that dangerous fungi like Aspergillus and Rhizopus were commonly present, especially in air ducts, and many of these fungi could resist common antifungal medications and disinfectants. The findings suggest that hospital environments serve as sources of infection for vulnerable patients and that better cleaning and air filtration systems are needed to protect hospitalized patients.

Saksenaea oblongispora Rhinosinusitis in Advanced HIV: A Rare and Lethal Mucormycosis

mycolabadmin

A 32-year-old man with advanced HIV developed a severe fungal infection of his sinuses caused by a rare fungus called Saksenaea oblongispora, which typically doesn’t affect people with HIV. The patient presented with severe facial swelling that rapidly worsened, and despite doctors identifying the fungus through biopsies and lab tests, he did not receive antifungal treatment or surgery before his condition became critical. This is the first case of this particular fungal infection documented in sub-Saharan Africa and in HIV patients, highlighting how dangerous this rare infection can be and how challenging it is to diagnose quickly enough to save lives.

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

During the COVID-19 pandemic, some patients developed a severe fungal infection called mucormycosis alongside their coronavirus infection. This study found that 63 COVID-19 patients in Iran developed mucormycosis, which primarily affected the sinuses and brain. The researchers identified that a fungus called Rhizopus arrhizus caused most infections, and patients who received corticosteroids (used to treat severe COVID-19) had a higher risk, especially those who developed diabetes from the steroids.

Disseminated Lichtheimia ramosa infection in a Japanese Black calf

mycolabadmin

A young calf developed a serious fungal infection caused by Lichtheimia ramosa despite treatment with multiple antibiotics. The calf had an underdeveloped thymus gland, making it vulnerable to infections. The fungus spread throughout the calf’s body, affecting the liver and digestive system. This case highlights how prolonged antibiotic use and weakened immunity can allow dangerous fungi to flourish.

Mucor germinans, a novel dimorphic species resembling Paracoccidioides in a clinical sample: questions on ecological strategy

mycolabadmin

Researchers identified a new fungal species called Mucor germinans from a patient with Burkitt lymphoma that can switch between filamentous and yeast-like forms. This is unusual because Mucor species are typically identified by their thread-like filaments, not budding yeast cells. The yeast form appeared at body temperature and resembled a different fungus called Paracoccidioides, potentially causing misdiagnosis. The discovery emphasizes the importance of recognizing that some Mucor infections may present with yeast-like cells and highlights the need for rapid, accurate identification to guide appropriate antifungal treatment.

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

This study found that COVID-19 patients in northwestern Iran who received high-dose steroid treatment developed serious fungal infections called mucormycosis. The infection was caused primarily by a fungus called Rhizopus arrhizus and affected mainly the sinuses and brain. The steroids used to treat COVID-19 weakened patients’ immune systems and triggered diabetes, both of which made them vulnerable to this dangerous fungal infection.

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report

mycolabadmin

A 74-year-old man with leukemia developed a serious fungal infection (mucormycosis) on his ankle while taking cancer-fighting drugs. The infection was diagnosed through tissue biopsy examination rather than standard culture tests. Treatment required both powerful antifungal medications and surgical removal of the infected leg below the knee. The patient recovered successfully after this aggressive treatment approach.

Research Keyword: Mucorales